Melanotan |
Melanotan 1 (Afamelanotide) 10mg is a synthetic peptide analogue of alpha-MSH (Melanocyte-stimulating hormone). Research focuses on its selective binding to melanocortin-1 receptors (MC1R) to stimulate melanogenesis and provide photoprotection without relying on high-level UV exposure.
Specifications
| Name | Melanotan 1 (Afamelanotide / MT-1) |
| Type | Research Peptide: MC1R Agonist |
| Amino Acid Count | 13 |
| Purity | ± 99% (HPLC – COA available) |
| Molecular Weight | 1646.85 g/mol |
| Analysis | HPLC, MS |
| Form | Lyophilized powder |
| Storage Conditions | 2-8°C (short-term) or -20°C (long-term) |
Confidential Lab Data - Specification Sheet
C78H111N21O19
Scientific History
Melanotan 1 (Afamelanotide) was developed in the 1980s by researchers at the University of Arizona. The objective was to create a stable, long-acting peptide that could stimulate melanin production in the skin, aiming to protect against sun damage and skin cancer.
Unlike its subsequent derivative Melanotan II, Melanotan 1 was designed to maintain a high level of receptor selectivity. This focused specificity allowed it to move into clinical trials as a protective agent for patients with light-sensitive skin disorders such as erythropoietic protoporphyria (EPP).
Mechanism of Action
Melanotan 1 exerts its effects primarily through the selective activation of melanocortin-1 receptors (MC1R) on cutaneous melanocytes. By mimicking endogenous alpha-MSH, it triggers melanin synthesis (eumelanin production), enhancing skin pigmentation and cellular protection against ultraviolet radiation without significant central nervous system activity.